GSK and Lilly will launch diabetes drugs to inject once a week within this year

The two new diabetes drugs, that need to be administered once a week, will enter the Korean market.

According to the industry concerned on the 8^th, GSK and Lilly are working to acquire domestic approvals for respective ‘Tanzeum (albiglutide)’ and ‘Trulicity (dulaglutide)’. It is expected that both of the drugs will acquire approvals by the first half of the year.

Their GLP-1 (Glucagon-Like Pe...